We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
+15.71%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$5.92B
AUM Growth
+$466M
Cap. Flow
-$28.9M
Cap. Flow %
-0.49%
Top 10 Hldgs %
26.27%
Holding
163
New
16
Increased
58
Reduced
30
Closed
24

Top Buys

Rank Stock Value
1
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$87.6M
2
GH icon
Guardant Health
GH
+$61.3M
3
MIRM icon
Mirum Pharmaceuticals
MIRM
+$37.2M
4
TOST icon
Toast
TOST
+$32M
5
LAD icon
Lithia Motors
LAD
+$28.4M

Top Sells

Rank Stock Value
1
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$71.9M
2
DOCS icon
Doximity
DOCS
+$45M
3
ENPH icon
Enphase Energy
ENPH
+$36M
4
ROP icon
Roper Technologies
ROP
+$31.6M
5
VECT
VectivBio Holding AG Ordinary Shares
VECT
+$31.6M

Sector Composition

Rank Sector Weight
1 Healthcare 43.76%
2 Technology 22.95%
3 Industrials 13.17%
4 Consumer Discretionary 7.97%
5 Utilities 3.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMLX icon
76
Amylyx Pharmaceuticals
AMLX
$2.31B
$24.1M 0.41%
1,116,837
+658,783
+144% +$17.8M
PLD icon
77
Prologis
PLD
$136B
$23.6M 0.4%
192,408
-25,808
-12% -$3.17M
KROS icon
78
Keros Therapeutics
KROS
$202M
$23.3M 0.39%
580,000
+280,000
+93% +$12.3M
NOVT icon
79
Novanta
NOVT
$4.95B
$23.2M 0.39%
126,017
+63
+0.1% +$10.3K
CWEN icon
80
Clearway Energy Class C
CWEN
$4.94B
$22M 0.37%
771,386
-525,338
-41% -$15.9M
MRTX
81
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$21.7M 0.37%
600,000
+228,898
+62% +$9.43M
AJG icon
82
Arthur J. Gallagher & Co
AJG
$65.9B
$21.4M 0.36%
97,599
-22,159
-19% -$4.61M
PNR icon
83
Pentair
PNR
$10.6B
$21.3M 0.36%
330,207
+58,702
+22% +$3.38M
NTLA icon
84
Intellia Therapeutics
NTLA
$1.55B
$20.1M 0.34%
493,222
– –
HCP
85
DELISTED
HashiCorp, Inc. Class A Common Stock
HCP
$19.6M 0.33%
+749,122
New +$22M
INSM icon
86
Insmed
INSM
$22B
$19.2M 0.33%
912,103
– –
CMS icon
87
CMS Energy
CMS
$22.7B
$18.9M 0.32%
321,314
+208,783
+186% +$12.6M
VCYT icon
88
Veracyte
VCYT
$4.77B
$18.6M 0.32%
732,000
– –
CYTK icon
89
Cytokinetics
CYTK
$10.9B
$18.1M 0.31%
556,000
– –
RCKT icon
90
Rocket Pharmaceuticals
RCKT
$351M
$17.8M 0.3%
898,000
– –
AKRO
91
DELISTED
Akero Therapeutics
AKRO
$17.7M 0.3%
379,120
– –
ALKS icon
92
Alkermes
ALKS
$8.39B
$17.6M 0.3%
+562,233
New +$17M
ROIV icon
93
Roivant Sciences
ROIV
$24.8B
$17M 0.29%
1,690,300
– –
RGEN icon
94
Repligen
RGEN
$7.03B
$16.8M 0.28%
119,000
– –
RARE icon
95
Ultragenyx Pharmaceutical
RARE
$2.56B
$16.6M 0.28%
359,000
– –
ELS icon
96
Equity Lifestyle Properties
ELS
$12.7B
$16.5M 0.28%
246,737
– –
BRKR icon
97
Bruker
BRKR
$9.79B
$16.3M 0.28%
220,803
– –
BBIO icon
98
BridgeBio Pharma
BBIO
$16.1B
$16.2M 0.27%
941,176
– –
XENE icon
99
Xenon Pharmaceuticals
XENE
$6.2B
$15.9M 0.27%
413,906
-227,294
-35% -$9.04M
CERE
100
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$15.6M 0.26%
490,000
+178,000
+57% +$5.46M
2 3
4
5 6

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q2 2023 Portfolio in Review

As of Q2 2023, Eventide Asset Management held 163 positions worth $5.92B, up 8.6% from $5.45B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Eventide Asset Management's Q2 2023 filing shows 16 new, 58 increased, 30 reduced and 24 closed positions. Its largest new stake was Toast: 1,603,866 shares worth $36.2M. The largest sale was Prometheus Biosciences, Inc. Common Stock, an estimated $71.9M.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, up from 43% a quarter earlier, followed by Technology and Industrials.

  • Eventide Asset Management's largest Q2 2023 buy was Toast: 1,603,866 shares worth $36.2M.
  • Eventide Asset Management added most to Zentalis Pharmaceuticals in Q2 2023, an estimated $87.6M increase.
  • Eventide Asset Management's biggest Q2 2023 reduction was Doximity, cutting an estimated $45M.
  • Eventide Asset Management fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $71.9M.
  • Eventide Asset Management's ten largest holdings make up 26% of its $5.92B portfolio in Q2 2023.
  • Eventide Asset Management opened 16 new positions and closed 24 in Q2 2023.
  • Eventide Asset Management's portfolio value rose 8.6% quarter-over-quarter to $5.92B.

Based on Eventide Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.